Skip to main content

In vivo human time-exposure study of orally dosed commercial silver nanoparticles.

By March 20, 2023No Comments


Human biodistribution, bioprocessing and possible toxicity of nanoscale silver receive increasing
health assessment. We prospectively studied commercial 10- and 32-ppm nanoscale silver particle
solutions in a single-blind, controlled, cross-over, intent-to-treat, design. Healthy subjects (n=60)
underwent metabolic, blood counts, urinalysis, sputum induction, and chest and abdomen magnetic
resonance imaging. Silver serum and urine content were determined. No clinically important changes
in metabolic, hematologic, or urinalysis measures were identified. No morphological changes were
detected in the lungs, heart or abdominal organs. No significant changes were noted in pulmonary
reactive oxygen species or pro-inflammatory cytokine generation. In vivo oral exposure to these
commercial nanoscale silver particle solutions does not prompt clinically important changes in human
metabolic, hematologic, urine, physical findings or imaging morphology. Further study of increasing
time exposure and dosing of silver nanoparticulate silver, and observation of additional organ
systems are warranted to assert human toxicity thresholds.

© 2013.

Study conducted using American Biotech Labs® 10ppm and 32ppm nano silver solutions.

KEYWORDS: Biological activity nanoparticles, Nanotechnology, Nanotoxicology oral ingestion, Safety

PMID: 23811290 [PubMed – as supplied by publisher]

LinkOut – more resources

www.ncbi.nim.nih.g ovipubmed/23811290 1″

Leave a Reply